Whitehawk Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Whitehawk Therapeutics, Inc. (formerly known as Aadi Bioscience, Inc.) is a clinical-stage oncology therapeutics company focused on developing next-generation antibody-drug conjugate (ADC) therapies. The company's advanced three-asset ADC portfolio—consisting of HWK-007, HWK-016, and HWK-206—is in-licensed from WuXi Biologics under an exclusive global development and commercialization agreement. These assets are engineered to target clinically validated tumor antigens (PTK7, MUC16, and SEZ6) while utilizing Hangzhou DAC's advanced linker-payload technology to overcome the therapeutic index and stability limitations of first-generation predecessors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the development of a three-asset antibody-drug conjugate (ADC) portfolio (HWK-007, HWK-016, and HWK-206) designed to target clinically validated proteins in high-potential cancer indications.
Expected impact: Establish clinical proof-of-concept and therapeutic index improvements over first-generation predecessors using the proprietary Carbon Bridge Cysteine Re-pairing (CBCR) platform.
Securing access to Hangzhou DAC's patented CPT113 linker-payload technology for use in up to five additional ADC programs.
Expected impact: Allows Whitehawk to select new targets, source antibodies, and expand its proprietary CBCR-based ADC platform while retaining global rights and full program control.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Divesting the Fyarro (nab-sirolimus) commercial business to Kaken Pharmaceutical to complete a strategic transformation from a commercial rare disease operator into a pure-play development-stage ADC platform.
Financial impact: Provided a $100 million upfront cash infusion, which, combined with concurrent private placements, extended the company's cash runway.
Strategic Partnerships
In-licensed the core three-asset ADC portfolio (HWK-007, HWK-016, and HWK-206) under an exclusive global development and commercialization agreement.
Terms: Includes development milestone expenses, such as $5.3 million recognized in Q1 2026.
Provides access to the patented CPT113 toxin-linker and CrossConju site-specific conjugation technology for up to five additional ADC programs.
Terms: DAC Biotech is entitled to corresponding milestone payments and product sales royalties under future product licensing agreements.